Efficacy of Smartphone Based Digital Application in Improving Headache Related Parameters in Patients With Migraine
NCT04984720 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 400
Last updated 2021-07-30
Summary
Migraine is a common headache disorder and affects 1 in 5 adults during their lifetime. It is a disorder which leads to significantly impaired quality of life, absence from work, loss of productivity in workplace and reduced vitality in social functioning. One of the important cornerstones in the management of migraine is the maintenance of a good headache diary. A headache diary enables the physician to understand the headache characteristics as well to establish the triggers causing the precipitation of episodes. The other important measure to ensure good outcomes is compliance to medications in those who have been prescribed prophylaxis. Migraine prophylaxis is by pills that have to be taken everyday at fixed time to ensure best outcomes. However, it is known that patients with migraine often are not adherent to prophylactic medications. A meta-analysis of 33 studies found that observational studies (n = 14) showed adherence ranging from 41% to 95% at 2 months after initiation of medication and 21% to 80% at 6 months. Pooled rates of persistence derived from 19 RCTs on propranolol, amitriptyline, and topiramate showed adherence rates of 77%, 55%, and 57%, respectively, at 16-26 weeks of initiation. The real world adherence is expected to be lower than that in the ideal settings of randomized trials. Regular pill reminders issued through smartphone based applications can improve medication adherence and thus improve headache outcomes. Though smartphone based migraine tracker digital applications are available, they mostly are aimed at capturing headache characteristics. The efficacy of providing pill reminders along with patient educational materials and community blog to enable migraineurs share their experiences with each other has not been studied in controlled trials. It is known that patients who are well informed about their chronic diseases such as migraine often have better outcomes. Busy clinicians often resort to providing pamphlets regarding the disease, triggers, acute pain relief medications, prophylactic therapy etc. However, it is yet to be studied if a digital application with all these inbuilt features, which are easily accessible at the finger tips would lead to better information uptake and improved compliance and self management. This RCT would try to assess this gap in knowledge.
Conditions
Interventions
- BEHAVIORAL
-
Smartphone based digital application
Smartphone Based Digital Application to Track Migraine, Offer Pill Reminders for Medication Adherence and Community Blog
Sponsors & Collaborators
-
All India Institute of Medical Sciences
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-07-25
- Primary Completion
- 2022-12-31
- Completion
- 2023-01-31
Countries
- India
Study Locations
More Related Trials
-
AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance
NCT06507150 ·Status: RECRUITING ·Phase: NA
-
Evaluation of a New Treatment for Migraine Attacks
NCT01880671 ·Status: COMPLETED ·Phase: NA
-
Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine
NCT04604977 ·Status: COMPLETED ·Phase: NA
-
Digital-technology Based Interventions on Treatment of Migraine.
NCT05458817 ·Status: UNKNOWN ·Phase: NA
-
Headache Provocation of People Who Are Unable to Have Headache
NCT04217668 ·Status: COMPLETED ·Phase: NA
-
Acupuncture as Migraine Prophylaxis in Reducing Frequency, Duration and Intensity of Migraine With Minimum Acupoint, Seen up to Eight Weeks From Baseline
NCT04509141 ·Status: COMPLETED ·Phase: NA
-
Mesotherapy Versus Systemic Therapyin Treatment of Migraine Headache
NCT04519346 ·Status: COMPLETED ·Phase: NA
-
Study With Migraid Device in Acute, Early Treatment of Migraine With Typical Aura
NCT00126035 ·Status: COMPLETED ·Phase: NA
-
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
NCT05853900 ·Status: COMPLETED ·Phase: NA
-
Sphenopalatine Ganglion Blockade in Migraine
NCT05210192 ·Status: UNKNOWN ·Phase: PHASE3
-
Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients with Chronic Migraine and Medication Overuse
NCT04389372 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Prophylaxis for Migraine Patients With Topiramate in India
NCT01836874 ·Status: COMPLETED
-
Brain Connectome for Acupuncture-treated Migraine Patients
NCT04157192 ·Status: UNKNOWN ·Phase: NA
-
A Study of Gastric Delay in Migraine Patients (3207-003)
NCT00548353 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505 ·Status: RECRUITING ·Phase: PHASE3
-
Nutritional Intervention in Migraine
NCT02703129 ·Status: COMPLETED ·Phase: NA
-
Brief Interventions in Chronic Migraine
NCT05979337 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
NCT06603558 ·Status: RECRUITING
-
Peripheral Nerve Block and Topiramate in the Treatment of Medication Overuse Headaches
NCT03767062 ·Status: COMPLETED ·Phase: NA
-
A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines
NCT01813591 ·Status: COMPLETED ·Phase: PHASE2
-
Facilitating Migraine Medication Adherence and Optimizing Medication Use
NCT02473692 ·Status: WITHDRAWN
-
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
NCT01435941 ·Status: COMPLETED
-
Facilitators and Barriers to Eptinezumab Administration in Thailand
NCT07035197 ·Status: COMPLETED
-
Migraine in Adolescents
NCT05654012 ·Status: RECRUITING ·Phase: NA
-
A Study Evaluating Oral Atogepant for the Prevention of Migraine in Japanese Participants With Chronic or Episodic Migraine
NCT04437433 ·Status: COMPLETED ·Phase: PHASE3